The Sinopharm factor: misinformation and logistical failures affect Chinese laboratory vaccine application | Vaccination | Coronavirus | EC data | LIME

According to the criteria of

Know more

The from the laboratory save lives, and , an intensive care physician and former president of the Peruvian Society of Intensive Medicine, is proof of this. The dose he received in February prevented the deterioration of his health picture and his death when he contracted the being exposed to the virus.

Sinopharm has increased its participation in immunization against COVID-19. In the last month and a half, the doses distributed in the country went from 1 million to more than 2.9 million, and currently represent 22% of the total distributed by the . However, the application does not progress the same.

If the pending agreements are finalized, by September the expected deliveries will add 17 million doses of Sinopharm, a figure similar to the accumulated reached for that date by Pfizer. Thus, we will have that, within two months, at least four out of every 10 doses received by the Government will be from Sinopharm.

SIGHT: Sinopharm vaccine prevents deaths from COVID-19

One of the main challenges of the Pedro Castillo government will be to accelerate the application of this vaccine, which is lagging behind. An analysis by the Data Journalism Unit of El Comercio determined that, to date, 58% of the doses of Sinopharm have been applied, a figure lower than that of Pfizer (91%) or Astrazeneca (88%).

(Elaboration: EC)
(Elaboration: EC)

Delay in the jungle

Although the Chinese vaccine is used throughout the country, in Amazonas, Loreto and Ucayali it has acquired a greater role and represents more than half of the doses.

However, also in this area there is a delay in its application. In the last two regions – where the most recent batch arrived on June 11 – only slightly more than 20% doses have been injected.

For Carlos Coral, infectious disease doctor at the Regional Hospital of , mistrust about the effectiveness of Sinopharm affects assistance to vaccination centers in Iquitos and other cities.

“The public thinks that Pfizer is better than Sinopharm, several with the first dose no longer want the second or are looking to migrate to Pfizer. At the height of the disease everyone wanted to get vaccinated, now they have relaxed. All vaccines protect you from serious forms “, Explain.

Loreto is one of the regions with the least advance in vaccination. Only 7% of its population is fully immunized.

In Ucayali, on the other hand, the problem is due to poor logistics and connectivity. Liz García, executive director of People’s Health of the Diresa Ucayali, points out that the native communities – where Sinopharm will be applied mostly – accept the vaccine, but resources are expected from the MEF for the purchase of boats and flights to border areas.

“We have 102 thousand people in rural areas and indigenous communities, we made a communication plan, but progress will be slow due to difficulties. There is a district and border province that have access only by air “, details.

New strategies

Percy Mayta-Tristán, Director of Research at the Southern Scientific University, points out that better communication should be done to confront the discrediting campaigns about the efficacy of the vaccine.

“The INS shared the study of effectiveness in health personnel. It was found that in the second wave, with high mortality, with the presence of lambda and gamma variants, Sinopharm was 94% effective in preventing deaths. Not all those who do not want to be vaccinated are anti-vaccines, but they do not have enough information “, opines.

Suggested video:

It may interest you:

.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.